Abnormal newborn screens and acylcarnitines in HIV-exposed and arv-exposed infants

Pediatric Infectious Disease Journal

Volumn 32, Issue 2, 2013, Pages 146-150

  Kirmse, Brian ^a   Hobbs, Charlotte V ^b   Peter, Inga ^c   Laplante, Bryan ^d   Caggana, Michele ^d   Kloke, Karen ^e   Raymond, Kimiyo ^e   Summar, Marshall ^a   Borkowsky, William ^f  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d WADSWORTH CENTER   (United States)

^e MAYO CLINIC   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

HIV AIDS; metabolism; mitochondrial toxicity; newborn screening

Indexed keywords

ACYLCARNITINE; ANTIRETROVIRUS AGENT; VIRUS ANTIBODY;

ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METABOLISM; NEWBORN; NEWBORN SCREENING; PLASMA; PRIORITY JOURNAL;

ANTI-RETROVIRAL AGENTS; CARNITINE; CASE-CONTROL STUDIES; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; NEONATAL SCREENING; NEW YORK;

EID: 84873059408     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31827030a6     Document Type: Article

References (31)

1. Dagan T, Sable C, Bray J, et al. Mitochondrial dysfunction and antiretro-viral nucleoside analog toxicities: what is the evidence? Mitochondrion. 2002;1:397-412.
2. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov. 2003;2: 812-822.
3. Divi RL, Leonard SL, Kuo MM, et al. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse tran-scriptase inhibitor-induced mitochondrial toxicity. Environ Mol Mutagen. 2007;48:201-209.
4. Arnaudo E, Dalakas M, Shanske S, et al. Depletion of muscle mitochon-drial DNA in AIDS patients with zidovudine-induced myopathy. Lancet. 1991;337:508-510.
5. Foster C, Lyall H. HIV and mitochondrial toxicity in children. J Antimicrob Chemother. 2008;61:8-12.
6. Lewis W, Kohler JJ, Hosseini SH, et al. Antiretroviral nucleosides, deoxynu-cleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS. 2006;20:675-684.
7. Alimenti A, Burdge DR, Ogilvie GS, et al. Lactic acidemia in human immunodefciency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J. 2003;22:782-789.
8. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084-1089.
9. Krivitzky L, Babikian T, Lee HS, et al. Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. Pediatr Res. 2009;66: 96-101.
10. Wilcken B. Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis. 2010;33:501-506.
11. Therrell BL, Johnson A, Williams D. Status of newborn screening programs in the United States. Pediatrics. 2006;117(5, pt 2):S212-S252.
12. Wilcken B, Wiley V, Hammond J, et al. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med. 2003; 348:2304-2312.
13. Sim KG, Carpenter K, Hammond J, et al. Acylcarnitine profles in fbro-blasts from patients with respiratory chain defects can resemble those from patients with mitochondrial fatty acid beta-oxidation disorders. Metab Clin Exp. 2002;51:366-371.
14. Rinaldo P, Cowan TM, Matern D. Acylcarnitine profle analysis. Genet Med. 2008;10:151-156.
15. Ilias I, Manoli I, Blackman MR, et al. L-Carnitine and acetyl-L-carnitine in the treatment of complications associated with HIV infection and antiretro-viral therapy. Mitochondrion. 2004;4:163-168.
16. Raymond K, Bale AE, Barnes CA, et al. Medium-chain acyl-CoA dehydro-genase defciency: sudden and unexpected death of a 45 year old woman. Genet Med. 1999;1:293-294.
17. Sewell AC, Böhles HJ. Acylcarnitines in intermediary metabolism. Eur J Pediatr. 1995;154:871-877.
18. Arnold GL, Salazar D, Neidich JA, et al. Outcome of infants diagnosed with 3-methyl-crotonyl-CoA-carboxylase defciency by newborn screening. Mol Genet Metab. 2012;106:439-441.
19. Ollenschläger G, Jansen S, Schindler J, et al. Plasma amino acid pattern of patients with HIV infection. Clin Chem. 1988;34:1787-1789.
20. Zangerle R, Kurz K, Neurauter G, et al. Increased blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective antiret-roviral therapy. Brain Behav Immun. 2010;24:403-408.
21. Gibson KM, Bennett MJ, Naylor E W, et al. 3-Methylcrotonyl-coenzyme A carboxylase defciency in Amish/Mennonite adults identifed by detection of increased acylcarnitines in blood spots of their children. J Pediatr. 1998;132(3, pt 1):519-523.
22. McGoey RR, Marble M. Positive newborn screen in a normal infant of a mother with asymptomatic very long-chain Acyl-CoA dehydrogenase def-ciency. J Pediatr. 2011;158:1031-1032.
23. Vijay S, Patterson A, Olpin S, et al. Carnitine transporter defect: diagnosis in asymptomatic adult women following analysis of acylcarnitines in their newborn infants. J Inherit Metab Dis. 2006;29:627-630.
24. Murphy WJ, Steiber A, Connery GC, et al. Altered carnitine metabolism in dialysis patients with reduced physical function may be due to dysfunctional fatty acid oxidation. Nephrol Dial Transplant. 2012;27:304-310.
25. Shneider BL, Rinaldo P, Emre S, et al. Abnormal concentrations of esterifed carnitine in bile: a feature of pediatric acute liver failure with poor prognosis. Hepatology. 2005;41:717-721.
26. Slaughter JL, Meinzen-Derr J, Rose SR, et al. The effects of gestational age and birth weight on false-positive newborn-screening rates. Pediatrics. 2010;126:910-916.
27. Igoudjil A, Abbey-Toby A, Begriche K, et al. High doses of stavudine induce fat wasting and mild liver damage without impairing mitochondrial respiration in mice. Antivir Ther (Lond). 2007;12:389-400.
28. Igoudjil A, Massart J, Begriche K, et al. High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes. Toxicol In Vitro. 2008;22:887-898.
29. Haas RH, Parikh S, Falk MJ, et al.; Mitochondrial Medicine Society's Committee on Diagnosis. The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab. 2008;94:16-37.
30. Jacotot E, Ravagnan L, Loeffer M, et al. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med. 2000;191:33-46.
31. World Health Organization, UNAIDS, UNICEF. Estimated number of women living with HIV needing and receiving antiretroviral medicine for PMTCT in low-and middle-income countries, 2010 [WHO website]. Available at: http://www.who.int/hiv/data/Table7-5-full.png. Accessed August 1, 2011.